+ Watch ENTA
on My Watchlist
Up, Up, & away
likely 5--10 bagger
achillion just collapsed so I guess zz is the man with the plan
Wow, how many hep C biopharmas can there be? Pharmasset, Inhibitex, and Anadys have already been bought out and Vertex, Achillion, and Idenix are still active players. To that number we can add Enanta, who went public in May and raised a modest 60M. Despite a respectable share price of 18.5, the market cap is only 330M. Compare that to Idenix at 650M and Achillion at 636M, despite those companies' recent misfortunes with clinical holds. Thus far, Enanta's drug candidates seem to be free of toxicity concerns and several phase III trials of HCV protease inhibitor ABT-450 combination therapies are in progress with topline data expected in the first half of 2014. Solid collaborations with AbbVie and Novartis would seem to position Enanta as a serious player in the race for hep C market share. Baker Bros has taken a small 125K share position, and the PropThink collaborative has published a detailed summary which aligns nicely with my own impressions. Enanta may be a chance for me to redeem myself for the vast opportunities I missed when the last generation of hep C stocks exploded in 2010 and 2011.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions